Alaunos Therapeutics Inc.
1 day chart
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. It is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. It is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR. Its TCR library consists of ten TCRs targeting six solid tumor indications, such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. Using its human neoantigen T cell Receptor discovery engine, it analyzes thousands of single T cells simultaneously using bioinformatics and next generation sequencing. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.
Buy US stocks in Australia starting with TCRT. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in TCRT
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.